Key Points
- Luke Evnin sold a total of 417,831 shares of Werewolf Therapeutics between Dec. 15 and Jan. 2 for roughly $285,600, and after the latest sale he directly owns 2,472,297 shares, a 0.75% decrease in his stake.
- Werewolf's stock traded around $0.64 (market cap about $31.3M) and has seen several recent downgrades, leaving an average analyst rating of Hold with a consensus price target of $3.75.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 18,568 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $0.63, for a total value of $11,697.84. Following the completion of the transaction, the director directly owned 2,472,297 shares in the company, valued at $1,557,547.11. This trade represents a 0.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Luke Evnin also recently made the following trade(s):
- On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.
- On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.61, for a total value of $21,256.67.
- On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
- On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total value of $22,448.16.
- On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.65, for a total transaction of $10,601.50.
- On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $44,999.64.
- On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $40,921.83.
- On Wednesday, December 17th, Luke Evnin sold 9,983 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total transaction of $11,380.62.
- On Tuesday, December 16th, Luke Evnin sold 14,548 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.05, for a total transaction of $15,275.40.
- On Monday, December 15th, Luke Evnin sold 23,640 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.07, for a total value of $25,294.80.
Werewolf Therapeutics Trading Up 1.8%
NASDAQ:HOWL opened at $0.64 on Friday. The business's 50-day moving average is $0.98 and its two-hundred day moving average is $1.27. The firm has a market capitalization of $31.30 million, a PE ratio of -0.40 and a beta of 0.77. Werewolf Therapeutics, Inc. has a 12 month low of $0.56 and a 12 month high of $2.38. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. Research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several research analysts have recently weighed in on HOWL shares. Zacks Research downgraded shares of Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 21st. Bank of America decreased their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, November 18th. Citizens Jmp downgraded Werewolf Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday, December 19th. Citigroup cut Werewolf Therapeutics from a "market outperform" rating to a "market perform" rating in a research note on Friday, December 19th. Finally, Wedbush lowered Werewolf Therapeutics from an "outperform" rating to a "neutral" rating and set a $1.00 price objective for the company. in a research note on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $3.75.
Check Out Our Latest Stock Analysis on Werewolf Therapeutics
Hedge Funds Weigh In On Werewolf Therapeutics
A number of hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $409,000. Citadel Advisors LLC acquired a new stake in shares of Werewolf Therapeutics during the 3rd quarter valued at approximately $304,000. Finally, Marshall Wace LLP bought a new position in Werewolf Therapeutics during the second quarter worth $113,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
